Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma

被引:0
作者
Cakmak, Erol [1 ]
Sari, Ismail [2 ]
Canoz, Ozlem [3 ]
Eser, Bulent [4 ]
Altuntas, Fevzi [5 ]
Cetin, Mustafa [4 ]
Unal, Ali [4 ]
机构
[1] Sivas Numune Hastanesi, Gastroenteroloji Klin, Sivas, Turkey
[2] Pamukkale Univ, Fac Med, Dept Hematol, Denizli, Turkey
[3] Erciyes Univ, Fac Med, Dept Pathol, Kayseri, Turkey
[4] Erciyes Univ, Fac Med, Dept Hematol, Kayseri, Turkey
[5] Ankara Oncol Training & Res Hosp, Dept Hematol, Ankara, Turkey
关键词
Lymphoma; P53; Bcl-2; Fas; prognosis;
D O I
10.5152/etd.2015.150001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: P53, Bcl-2, and Fas proteins play significant roles in lymphoid cell apoptosis. These proteins affect the prognosis and treatment response of lymphoma and various malignancies. The aim of the present study was to investigate the effects of P53, Bcl-2, and Fas protein expression on treatment and prognosis in patients with primary gastrointestinal diffuse large B-cell lymphoma. Materials and Methods: Thirty-nine patients with primary gastrointestinal diffuse large B-cell lymphoma were included in the study. Immunohistochemical staining was performed to analyze P53, Bcl-2, and Fas protein expression levels in paraffin sections. Results: We examined 39 patients with primary gastrointestinal diffuse large B-cell lymphoma, 21 males and 18 females, with a median age of 54 years. P53 protein expression was detected in 24 patients (61.5%), Bcl-2 protein expression was detected in 26 (67%), and Fas protein expression was detected in 28 (72%). The five-year overall survival rate was significantly lower in patients with P53 and Bcl-2 expression; on the other hand, we did not find a significant difference in the five-year overall survival with respect to Fas protein expression. Conclusion: We found that P53 and Bcl-2 protein expression had a negative effect on prognosis and survival in patients with primary gastrointestinal diffuse large B-cell lymphoma. However, Fas protein expression had no effect on prognosis and survival. Taken together, patients with P53 and Bcl-2 expression should be considered to have a high risk from the beginning, and these patients should undergo aggressive treatments.
引用
收藏
页码:102 / 105
页数:4
相关论文
共 26 条
  • [1] Arican A, 1999, AM J CLIN ONCOL-CANC, V22, P587
  • [2] Role of Bcl-2 family of proteins in malignancy
    Baliga, BC
    Kumar, S
    [J]. HEMATOLOGICAL ONCOLOGY, 2002, 20 (02) : 63 - 74
  • [3] CANCER PROGRESSION AND P53
    CARSON, DA
    LOIS, A
    [J]. LANCET, 1995, 346 (8981): : 1009 - 1011
  • [4] Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma
    Chatzitolios, Anastasios
    Venizelos, Ioannis
    Tripsiannis, Gregory
    Anastassopoulos, George
    Papadopoulos, Nikolaos
    [J]. ANNALS OF HEMATOLOGY, 2010, 89 (09) : 889 - 896
  • [5] Apoptosis in hematological disorders
    Debatin, KM
    Stahnke, K
    Fulda, S
    [J]. SEMINARS IN CANCER BIOLOGY, 2003, 13 (02) : 149 - 158
  • [6] Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma
    Eser, B
    Sari, I
    Canoz, Z
    Altuntas, F
    Cakmak, E
    Ozturk, A
    Ozkan, M
    Er, O
    Cetin, M
    Unal, A
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (05) : 307 - 314
  • [7] Gascoyne RD, 1997, BLOOD, V90, P244
  • [8] Grogan TM, 2001, CANC TREATMENT, P1338
  • [9] Hazar B, 1997, ONCOLOGY, V54, P84
  • [10] Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma
    Hermine, O
    Haioun, C
    Lepage, E
    dAgay, MF
    Briere, J
    Lavignac, C
    Fillet, G
    Salles, G
    Marolleau, JP
    Diebold, J
    Reyes, F
    Gaulard, P
    [J]. BLOOD, 1996, 87 (01) : 265 - 272